Efficacy of a mephentermine‐based product as a vasopressor and a cardiac performance enhancer when given intramuscularly to cattle

The goal of this study was to confirm the vasopressor and cardiac effects of POTENAY^® INJETÁVEL (POT), a mephentermine‐based product, given to cattle with induced vascular/cardiac depression. Ten healthy Holstein cattle (206 ± 13 kg) followed a randomized‐complete‐block design (RCBD) utilizing crossover study design. Each animal randomly received (1 ml/25 kg, IM) of either POT (n = 10) or volume‐matched placebo control (0.9%NaCl, CP, n = 10). A subset of animals (n = 5) received POT first (day 0) while the remaining (n = 5) received CP; after a six‐day washout period, cattle received the opposite compound. Animals were anesthetized and catheterized for systemic/left ventricular hemodynamic monitoring. Myocardial dysfunction/hypotension was induced by increasing the end‐tidal isoflurane concentration until arterial blood pressure was 20% lower than at baseline and remained stable. Once the animal was determined to be hypotensive and hemodynamically stable, steady‐state hypotensive baseline data (BL2) were acquired, and treatment with either POT or CP was given. Data were acquired post‐treatment at every 15 min for 90 min. POT improved cardiac output (+68 L/min, ±14%, p < 0.05), MAP (+14 mmHg, ±4%, p < 0.05), HR (+22 bpm, ±8%, p < 0.05), and peak rates of ventricular pressure change during both systole (dP/dt_max: +37 mmHg/s ±13%, p < 0.05) and diastole (dP/dt_min: +31 mmHg/s, ±7%, p < 0.05). No improvements were noted following placebo‐control administration. Results indicate that POT improves cardiac performance and systemic hemodynamics in cattle with induced cardiovascular depression when given as single intramuscular injection.     

Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2

Canine histiocytic sarcoma (HS) is an aggressive and highly metastatic tumor. Previously, the kinase inhibitor dasatinib was shown to have potent growth inhibitory activity against HS cells in vitro, possibly via targeting the EPHA2 receptor. Here, the in vivo effect of dasatinib in HS cells was investigated using a xenograft mouse model. Moreover, the expression status of EPHA2 was examined in six HS cell lines, ranging from insensitive to highly sensitive to dasatinib. In the HS xenograft mouse model, dasatinib significantly suppressed tumor growth, as illustrated by a decrease in mitotic and Ki67 indices and an increase in apoptotic index in tumor tissues. On Western blot analysis, EPHA2 was only weakly detected in all HS cell lines, regardless of sensitivity to dasatinib. Dasatinib likely results in the inhibition of xenograft tumor growth via a mechanism other than targeting EPHA2. The findings of this study suggest that dasatinib is a targeted therapy drug worthy of further exploration for the treatment of canine HS.     

Review of triazine antiprotozoal drugs used in veterinary medicine

Triazines are relatively new antiprotozoal drugs that have successfully controlled coccidiosis and equine protozoal myeloencephalitis. These drugs have favorably treated other protozoal diseases such as neosporosis and toxoplasmosis. In this article, we discuss the pharmacological characteristics of five triazines, toltrazuril, ponazuril, clazuril, diclazuril, and nitromezuril which are used in veterinary medicine to control protozoal diseases which include coccidiosis, equine protozoal myeloencephalitis, neosporosis, and toxoplasmosis.     

Noninferiority trial investigating the efficacy of a nonantibiotic intramammary therapy in the treatment of mild‐to‐moderate clinical mastitis in dairy cows with longer lasting udder diseases

A nonblinded, positively controlled, noninferiority trial was conducted to evaluate the efficacy of an alternative, nonantibiotic therapy with Masti Veyxym^® to reduce ineffective antibiotic usage in the treatment of nonsevere clinical mastitis (CM) in cows with longer lasting udder diseases. The solely intramammary treatment with Masti Veyxym^® (three applications, 12 hr apart) and the combined treatment with Masti Veyxym^® and antibiotics as usual on the farm according to label of the respective product were compared with the reference treatment of solely antibiotic therapy. The matched field study was conducted on eight free‐stall dairy farms located in Eastern Germany. Cases of mild‐to‐moderate CM in cows with longer lasting high somatic cell counts in preceding dairy herd improvement test days and with previous CM cases in current lactation were randomly allocated to one of the three treatment groups. A foremilk sample of the affected quarter was taken before treatment and again approximately 14 days and 21 days after the end of therapy for cyto‐bacteriological examination. Primary outcomes were clinical cure (CC) and no CM recurrence within 60 days after the end of treatment (no R60). Bacteriological cure (BC) and quarter somatic cell count (QSCC) cure were chosen as secondary outcomes although low probabilities of BC and QSCC cure for selected cows were expected. The study resulted in the following findings: the pathogens mostly cultured from pretreatment samples were Streptococcus uberis, followed by Staphylococcus aureus and coagulase‐negative staphylococci. There were no significant differences between the two test treatments in comparison with the reference treatment regarding all outcome variables. The sole therapy with Masti Veyxym^® resulted in a numerically lower likelihood of BC without significant differences to the reference treatment. The combined therapy group showed a numerically higher nonrecurrence rate than the two other treatment groups and noninferiority compared to the reference treatment was proven. Having regard to the selection criteria of cows in this study, the findings indicated that sole treatment with Masti Veyxym^® in nonsevere CM cases may constitute an alternative therapy to reduce antibiotics. However, noninferiority evaluations were mostly inconclusive. Further investigations with a larger sample size are required to confirm the results and to make a clear statement on noninferiority.     

Effect of dietary inclusion of date seed (<Emphasis Type="Italic">Phoenix dactylifera</Emphasis> L.) on intake,digestibility, milk production,and milk fatty acid profile of Holstein dairy cows

The objective of this experiment was to investigate the influence of ground date seed (GDS) on intake, digestibility, and milk yield and milk fatty acid (FA) composition of lactating Holstein cows. The experimental design was a 4?×?4 replicated Latin square with eight lactating dairy cows with an average milk production of 35.5?±?1.5 kg and 75?±?5 days in milk (DIM). Dairy cows were fed one of the four treatments contained 0, 2, 4, and 6% of diet dry matter (DM) GDS in replacement of wheat bran. All diets contained the same amount of forages (alfalfa hay and corn silage). Dietary treatments had no effect on DM intake (DMI), total tract apparent digestibility, milk yield, and milk composition. Increasing GDS linearly decreased concentration of C13:0 and increased cis-9 C14:1 and trans-11 C18:1 (vaccenic acid) (P?<?0.05). A linear tendency for more C16:1 content in milk fat was observed with increasing GDS (P?=?0.06). Feeding GDS resulted in a linear decrease (P?<?0.01) in saturated FA (SFA) but increased milk fat monounsaturated FA (MUFA) and trans FA (TFA) (P?<?0.05). Therefore, low levels of GDS (up to 6%) in the diet of Holstein dairy cows can beneficially modify milk FA composition without any adverse effects on intake, digestibility, and milk yield.     

Genetic evaluation of growth in farmers’ flocks of Madras Red sheep under long-term selection in a group breeding scheme

The Network Project on Sheep Improvement (NWPSI)–Madras Red field unit is a group breeding scheme involving 198 farmers’ flocks of Madras Red sheep in which selection for growth traits and rotation of rams have been practised for over two decades. Growth data collected from these flocks were used to evaluate the performance and understand the direct and expected responses to selection based on genetic parameters. The body weight at birth (BW), weaning weight (WW), 6-month weight (6W), 9-month weight (9W), 12-month weight (YW), pre-weaning average daily gain (ADG1, birth to 3 months), post-weaning ADG2 (3–6 months), ADG3 (6–9 months), ADG4 (9–12 months) and ADG5 (3–12 months) were 2.67, 10.05, 14.56, 18.36, 21.36, 80.13, 49.05, 43.00, 34.21 and 41.18 g, respectively. Univariate analyses were carried out using animal and sire models to estimate variance components. Heritability obtained from animal model for BW was 0.36 and the values for other body weight traits were almost unity. Heritability estimate for pre-weaning ADG1 was 0.31. Very high genetic variability was observed in spite of long-term selection and this sustenance of variability is one of the main advantages of a group breeding scheme, combining several flocks of smaller size. An increasing genetic and phenotypic trend was noticed for almost all the traits studied. The expected responses calculated based on genetic parameters also indicated scope for improvement.